Definitive chemoradiation for oligometastatic esophageal cancer patients. PIONEER: A multicenter, open-label, randomized phase II trial of second-line apatinib plus chemotherapy versus chemotherapy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback